Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase

Molecular Cell

Volumn 2, Issue 5, 1998, Pages 581-591

  Dihua, Yu ^a   Jing, Tong ^a   Liu, Bolin ^a   Yao, Jun ^a   Tan, Ming ^a   McDonnell, Timothy J ^a   Hung, Mien Chie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CDK2 PROTEIN, HUMAN; CDK2 PROTEIN, MOUSE; CDKN1A PROTEIN, HUMAN; CDKN1A PROTEIN, MOUSE; CYCLIN B; CYCLIN B1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DNA FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KINETIN; OLOMOUCINE; PACLITAXEL; PROTEIN SERINE THREONINE KINASE; PURINE DERIVATIVE;

ANIMAL; APOPTOSIS; ARTICLE; BREAST TUMOR; CELL CULTURE; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; FIBROBLAST; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOUSE; PATHOLOGY; UPREGULATION;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CDC2 PROTEIN KINASE; CDC2-CDC28 KINASES; CELL LINE; CYCLIN B; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; DNA FRAGMENTATION; FIBROBLASTS; FLOW CYTOMETRY; HUMANS; KINETIN; MICE; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; PROTEIN-SERINE-THREONINE KINASES; PURINES; RECEPTOR, ERBB-2; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0032214980     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1097-2765(00)80157-4     Document Type: Article

References (30)

1. Barboule, N., Chadebech, P., Baldin, V., Vidal, S., and Valette, A. (1997). Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene 15, 2867-2875.
2. Blagosklonny, M.V., Schulte, T., Nguyen, P., Trepel, J., and Neckers, L.M. (1996). Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res. 56, 1851-1854.
3. Coleman, T.R., and Dunphy, W.G. (1994). Cdc2 regulatory factors. Curr. Opin. Cell Biol. 6, 877-882.
4. Collins, M.K.L., and Rivas, A.L. (1993). The control of apoptosis in mammalian cells. Trends Biochem. Sci. 18, 307-309.
5. Darzynkiewicz, Z., Bruno, S., Del Bino, G., Gorczyca, W., Hotz, M.A., Lassota, P., and Traganos, F. (1992). Features of apoptotic cells measured by flow cytometry. Cytometry 13, 795-808.
6. Dickman, S. (1998). Antibodies stage a comeback in cancer treatment. Science 280, 1196-1197.
7. Ding, A.H., Porteu, F., Sanchez, E., and Nathan, C.F. (1990). Shared actions of endotoxin and Taxol on TNF receptors and TNF release. Science 248, 370-372.
8. cdc2 coincident with Taxol-induced apoptosis. Cell Growth Differ. 5, 1041-1050.
9. Draetta, G., Luca, F., Westendorf, J., Brizuela, L., Reuderman, J., and Beach, D. (1989). Cdc2 protein kinase is complexed with both cyclin A and B: evidence for proteolytic inactivation of MPF. Cell 56, 829-838.
10. cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol. Cell. Biol. 18, 546-557.
11. El-Deiry, W., Tokino, T., Velculescu, V.E., Levy, D.B., Parson, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., and Voglestein, B. (1993). Waf1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
12. Fisher, D.E. (1994). Apoptosis in cancer therapy: crossing the threshold. Cell 78, 539-542.
13. Guadagno, T.M., and Newport, J.W. (1996). Cdk2 kinase is required for entry into mitosis as a positive regulator of cdc2-cyclin B kinase activity. Cell 84, 73-83.
14. Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K., and Elledege, S.J. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816.
15. Holmes, F.A., Walters, R.S., Theriault, R.L., Forman, A.D., Newton, L.K., Raber, M.N., Buzdar, A.U., Frye, D.K., and Hortobagyi, G.N. (1991). Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst. 83, 1797-1805.
16. Horwitz, S.B. (1992). Mechanism of action of Taxol. Trends Pharmacol. Sci. 13, 134-136.
17. Jacks, T., and Weinberg, R.A. (1996). Cell-cycle control and its watchman. Nature 381, 643-644.
18. Lesoon-Wood, L.A., Kim, W.H., Kleinman, H.K., Weintraub, B.D., and Mixson, A.J. (1995). Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum. Gene Ther. 6, 395-405.
19. Manthey, C.L., Brandes, M.E., Perera, P.Y., and Vogel, S.N. (1992). Taxol increases steady-state levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages. J. Immunol. 149, 2459-2465.
20. Meikrantz, W., and Schlegel, R. (1996). Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases. J. Biol. Chem. 271, 10205-10209.
21. Montes de Oca Luna, R., Amelse, L.L., Chavez-Reyes, A., Evans, S.C., Brugarolas, J., Jacks, T., and Lozano, G. (1997). Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nat. Genet. 16, 336-337.
22. 2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell. Biol. 18, 629-643.
23. Rodeck, U., Jost, M., Kari, C., Shih, D.T., Lavker, R.M., Ewert, D.L., and Jensen, P.J. (1997). EGF-R dependent regulation of keratinocyte survival. J. Cell Sci. 110, 113-121.
24. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neuoncogene. Science 235, 177-182.
25. van den Heuvel, S., and Harlow, E. (1993). Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262, 2050-2054.
26. Vesely, J., Havlicek, L., Strnad, M., Blow, J.J., Donella-Deana, A., Pinna, L., Letham, D.S., Kato, J.Y., Detivaud, L., Leclerc, S., and Meijer, L. (1994). Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224, 771-786.
27. Wahl, A.F., Donaldson, K.L., Fairchild, C., Lee, F.Y.F., Foster, S.A., Demers, G.W., and Galloway, D.A. (1996). Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2, 72-79.
28. Waldman, T., Lengauer, C., Kinzler, K.W., and Vogelstein, B. (1996). Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381, 713-716.
29. Yu, D., Suen, T.-C., Van, D.-H., Chang, L.S., and Hung, M.-C. (1990). Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc. Natl. Acad. Sci. USA 87, 4499-4503.
30. Yu, D., Liu, B., Tan, M., Li, J., Wang, S.-S., and Hung, M.-C. (1996). Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 13, 1359-1365.